Pacer Advisors Inc. Cuts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Pacer Advisors Inc. lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 53.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 4,478 shares of the biopharmaceutical company’s stock after selling 5,110 shares during the period. Pacer Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,482,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $243,000. Geneos Wealth Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares during the period. Flow Traders U.S. LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $241,000. Daiwa Securities Group Inc. boosted its position in Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in Alnylam Pharmaceuticals by 70,300.0% during the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 703 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $455 price target. Although the firm lowered its 2026, 2028, 2029 and 2030 EPS forecasts, it raised its FY2027 estimate to $9.50 from $8.13, signaling expectations for continued longer-term earnings growth. HC Wainwright estimates for Alnylam Pharmaceuticals
• Neutral Sentiment: Several HC Wainwright revisions reduced projected EPS, including Q3 2026 to $1.65 from $1.79, Q4 2026 to $1.97 from $2.23, and FY2026 to $6.30 from $6.51. The firm’s estimates remain broadly positive beyond 2026, reaching $19.42 per share by FY2030, but the near-term reductions could limit enthusiasm. Alnylam Pharmaceuticals earnings estimates
• Neutral Sentiment: An AAII comparison examines whether Alnylam or Halozyme Therapeutics is the more attractive investment. The article may influence investor preferences, but it does not identify a new company-specific operating catalyst. Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. Stock?
• Neutral Sentiment: Options-market implied volatility for ALNY has surged, pointing to increased expectations for price movement and trading risk rather than a clear bullish or bearish fundamental signal. Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
• Negative Sentiment: Truist Financial lowered its price target on Alnylam to $315, a more cautious valuation view that could weigh on the stock and reflects concern about the company’s risk-reward profile. Truist Financial Lowers Alnylam Pharmaceuticals Price Target

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright reduced their price target on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. JPMorgan Chase & Co. decreased their price target on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $396.72.

Alnylam Pharmaceuticals Stock Up 1.4%

Alnylam Pharmaceuticals stock opened at $219.20 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The business has a fifty day moving average price of $280.12 and a 200-day moving average price of $306.27. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 3.06. The stock has a market capitalization of $29.33 billion, a price-to-earnings ratio of 40.74 and a beta of 0.30.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.